Halozyme Therapeutics Inc (HALO)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	388,181	359,040	341,028	268,516	287,962	269,734	268,571	330,362	302,474	244,469	166,029	67,656	12,620	12,443	15,835	19,121	20,502	19,555	18,326	18,090
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Gross profit margin		47.90%	47.09%	45.32%	39.19%	44.78%	47.64%	56.10%	71.17%	69.41%	53.43%	40.61%	20.54%	4.72%	6.24%	8.77%	11.63%	10.46%	9.65%	10.08%	10.17%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $388,181K ÷ $810,397K
= 47.90%

The gross profit margin of Halozyme Therapeutics Inc. has exhibited a gradual decline over the recent quarters, with a decrease from 78.90% in Q4 2022 to 76.80% in Q4 2023. This downward trend suggests a potential erosion of the company's ability to generate profits from its core operations. Moreover, the figures indicate that the company may be facing challenges in maintaining its cost efficiencies and pricing strategies, impacting its profitability. Further investigation into the reasons behind this decline is warranted to assess the company's overall financial health and performance.